Research ExplorerPublicationsAllogeneic hematopoietic cell transplantation for patients w...

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Standard

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). / Maffini, Enrico; Ngoya, Maud; Galimard, Jacques-Emmanuel; Harbi, Samia; Kröger, Nicolaus; Platzbecker, Uwe; Sengeloev, Henrik; Craddock, Charles; Potter, Victoria; Choi, Goda; Chevallier, Patrice; Stölzel, Friedrich; Tholouli, Eleni; Maertens, Johan; Ciceri, Fabio; Cornelissen, Jan; Sanz, Jaime; Spyridonidis, Alexandros; Lanza, Francesco; Nagler, Arnon; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 58, No. 9, 09.2023, p. 1033-1041.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Maffini, E, Ngoya, M, Galimard, J-E, Harbi, S, Kröger, N, Platzbecker, U, Sengeloev, H, Craddock, C, Potter, V, Choi, G, Chevallier, P, Stölzel, F, Tholouli, E, Maertens, J, Ciceri, F, Cornelissen, J, Sanz, J, Spyridonidis, A, Lanza, F, Nagler, A & Mohty, M 2023, 'Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)', BONE MARROW TRANSPL, vol. 58, no. 9, pp. 1033-1041. https://doi.org/10.1038/s41409-023-02027-y

APA

Maffini, E., Ngoya, M., Galimard, J-E., Harbi, S., Kröger, N., Platzbecker, U., Sengeloev, H., Craddock, C., Potter, V., Choi, G., Chevallier, P., Stölzel, F., Tholouli, E., Maertens, J., Ciceri, F., Cornelissen, J., Sanz, J., Spyridonidis, A., Lanza, F., ... Mohty, M. (2023). Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPL, 58(9), 1033-1041. https://doi.org/10.1038/s41409-023-02027-y

Vancouver

Maffini E, Ngoya M, Galimard J-E, Harbi S, Kröger N, Platzbecker U et al. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPL. 2023 Sep;58(9):1033-1041. https://doi.org/10.1038/s41409-023-02027-y

Bibtex

@article{de4ccc6093634536b9bb60672dc7367e,
title = "Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)",
abstract = "Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged ≥70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.",
keywords = "Aged, Humans, Acute Disease, Bone Marrow, Hematopoietic Stem Cell Transplantation/adverse effects, Leukemia, Myeloid, Acute, Prospective Studies, Recurrence, Retrospective Studies, Transplantation Conditioning, Unrelated Donors, Graft vs Host Disease",
author = "Enrico Maffini and Maud Ngoya and Jacques-Emmanuel Galimard and Samia Harbi and Nicolaus Kr{\"o}ger and Uwe Platzbecker and Henrik Sengeloev and Charles Craddock and Victoria Potter and Goda Choi and Patrice Chevallier and Friedrich St{\"o}lzel and Eleni Tholouli and Johan Maertens and Fabio Ciceri and Jan Cornelissen and Jaime Sanz and Alexandros Spyridonidis and Francesco Lanza and Arnon Nagler and Mohamad Mohty",
note = "{\textcopyright} 2023. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2023",
month = sep,
doi = "10.1038/s41409-023-02027-y",
language = "English",
volume = "58",
pages = "1033--1041",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

AU - Maffini, Enrico

AU - Ngoya, Maud

AU - Galimard, Jacques-Emmanuel

AU - Harbi, Samia

AU - Kröger, Nicolaus

AU - Platzbecker, Uwe

AU - Sengeloev, Henrik

AU - Craddock, Charles

AU - Potter, Victoria

AU - Choi, Goda

AU - Chevallier, Patrice

AU - Stölzel, Friedrich

AU - Tholouli, Eleni

AU - Maertens, Johan

AU - Ciceri, Fabio

AU - Cornelissen, Jan

AU - Sanz, Jaime

AU - Spyridonidis, Alexandros

AU - Lanza, Francesco

AU - Nagler, Arnon

AU - Mohty, Mohamad

N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2023/9

Y1 - 2023/9

N2 - Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged ≥70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.

AB - Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701 adults aged ≥70 years, with acute myeloid leukemia (AML) in first complete remission (CR1), who received a first HCT, from HLA-matched sibling donors (MSD), 10/10 HLA-matched unrelated donors (UD), 9/10 HLA-mismatched unrelated donors (mUD) or haploidentical (Haplo) donors. The 2-year overall survival (OS) was 48.1%, leukemia-free survival (LFS) 45.3%, relapse incidence (RI) 25.2%, non-relapse mortality (NRM) 29.5% and GVHD-free, relapse-free survival (GRFS), 33.4%. Compared to MSD, patients transplanted from Haplo and UD presented lower RI (HR 0.46, 95% CI 0.25-0.8, p = 0.02 and HR 0.44, 95% CI: 0.28-0.69, p = 0.001, respectively); this translated into prolonged LFS for Haplo (HR 0.62, 95% CI: 0.39-0.99, p = 0.04). Patients transplanted from mUD exhibited the highest NRM incidence (HR 2.33, 95% CI: 1.26-4.31, p = 0.007). HCT in selected adult CR1 AML patients >70 years is feasible and could be associated with good clinical outcomes. Prospective clinical trials are warranted.

KW - Aged

KW - Humans

KW - Acute Disease

KW - Bone Marrow

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Leukemia, Myeloid, Acute

KW - Prospective Studies

KW - Recurrence

KW - Retrospective Studies

KW - Transplantation Conditioning

KW - Unrelated Donors

KW - Graft vs Host Disease

U2 - 10.1038/s41409-023-02027-y

DO - 10.1038/s41409-023-02027-y

M3 - SCORING: Journal article

C2 - 37386253

VL - 58

SP - 1033

EP - 1041

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 9

ER -